Development of Selective Inhibitors and Substrate of Matrix Metalloproteinase-12*
暂无分享,去创建一个
Philippe Cuniasse | F. Beau | V. Dive | P. Cuniasse | L. Devel | Laurent Devel | Fabrice Beau | Vincent Dive | Vassilis Rogakos | Arnaud David | Anastasios Makaritis | Athanasios Yiotakis | A. Yiotakis | Arnaud David | A. Makaritis | V. Rogakos
[1] J. Foidart,et al. Purification of active matrix metalloproteinase catalytic domains and its use for screening of specific stromelysin-3 inhibitors. , 1999, Protein expression and purification.
[2] Jason L. Johnson,et al. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[3] R. Pierce,et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. , 1998, Journal of immunology.
[4] H. V. Van Wart,et al. Understanding the P1' specificity of the matrix metalloproteinases: effect of S1' pocket mutations in matrilysin and stromelysin-1. , 1996, Biochemistry.
[5] C. Brinckerhoff,et al. Matrix metalloproteinases: role in arthritis. , 2006, Frontiers in bioscience : a journal and virtual library.
[6] N. Kaminski,et al. Loss of integrin αvβ6-mediated TGF-β activation causes Mmp12-dependent emphysema , 2003, Nature.
[7] R. Powers,et al. Impact of mobility on structure-based drug design for the MMPs. , 2002, Journal of the American Chemical Society.
[8] Z. Werb,et al. New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.
[9] F. Beau,et al. Phosphinic peptides as zinc metalloproteinase inhibitors , 2004, Cellular and Molecular Life Sciences CMLS.
[10] A. Vogel,et al. Vogel's Textbook of Practical Organic Chemistry , 2003 .
[11] Synthesis and evaluation of novel oxazoline MMP inhibitors. , 2004, Bioorganic & medicinal chemistry letters.
[12] G Murphy,et al. A novel coumarin‐labelled peptide for sensitive continuous assays of the matrix metalloproteinases , 1992, FEBS letters.
[13] V. Wee Yong,et al. Metalloproteinases in biology and pathology of the nervous system , 2001, Nature Reviews Neuroscience.
[14] M. Daheshia. Therapeutic inhibition of matrix metalloproteinases for the treatment of chronic obstructive pulmonary disease (COPD) , 2005, Current medical research and opinion.
[15] F. Mannello,et al. Matrix metalloproteinase inhibitors as anticancer therapeutics. , 2005, Current cancer drug targets.
[16] Pierre Ducrot,et al. Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[17] V. Dive,et al. Diastereoselective solution and multipin-based combinatorial array synthesis of a novel class of potent phosphinic metalloprotease inhibitors. , 2003, Chemistry.
[18] B. Fingleton,et al. Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.
[19] D. Moras,et al. Crystal structure of the stromelysin-3 (MMP-11) catalytic domain complexed with a phosphinic inhibitor mimicking the transition-state. , 2001, Journal of molecular biology.
[20] P. Basset,et al. Membrane Type-1 Matrix Metalloprotease and Stromelysin-3 Cleave More Efficiently Synthetic Substrates Containing Unusual Amino Acids in Their P1′ Positions* , 1998, The Journal of Biological Chemistry.
[21] G. Rosenberg. Matrix metalloproteinases biomarkers in multiple sclerosis , 2005, The Lancet.
[22] A. Morgan,et al. Differences in Matrix Metalloproteinase-1 and Matrix Metalloproteinase-12 Transcript Levels Among Carotid Atherosclerotic Plaques With Different Histopathological Characteristics , 2004, Stroke.
[23] Sophie Perrier,et al. Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12. , 2004, Journal of molecular biology.
[24] Ivano Bertini,et al. Conformational variability of matrix metalloproteinases: beyond a single 3D structure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[25] Nasreen S Jessani,et al. Activity-based probes for the proteomic profiling of metalloproteases. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[26] H. Tanaka,et al. Inhibitors of acyl-CoA:cholesterol O-acyltransferase (ACAT). Part 1: identification and structure-activity relationships of a novel series of substituted N-alkyl-N-biphenylylmethyl-N'-arylureas. , 1998, Bioorganic & medicinal chemistry.
[27] Mark D. Huffman,et al. Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. , 1998, The Journal of clinical investigation.
[28] Naoyuki Taniguchi,et al. Dysregulation of TGF-beta1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[29] W. Bode. Structural basis of matrix metalloproteinase function. , 2003, Biochemical Society symposium.
[30] A. Levitzki,et al. An accurate method for determination of receptor-ligand and enzyme-inhibitor dissociation constants from displacement curves. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[31] S. Shapiro,et al. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. , 1997, Science.
[32] M. Karplus,et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .
[33] C. López-Otín,et al. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. , 2004, The International journal of developmental biology.
[34] G. Lip,et al. Matrix metalloproteinases in coronary artery disease: clinical and therapeutic implications and pathological significance. , 2005, Current Medicinal Chemistry.
[35] A. Newby,et al. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. , 2005, Physiological reviews.
[36] V. Dive,et al. Protection of the Hydroxyphosphinyl Function of Phosphinic Dipeptides by Adamantyl. Application to the Solid-Phase Synthesis of Phosphinic Peptides. , 1996, The Journal of organic chemistry.
[37] A. Luttun,et al. Loss of Matrix Metalloproteinase-9 or Matrix Metalloproteinase-12 Protects Apolipoprotein E–Deficient Mice Against Atherosclerotic Media Destruction but Differentially Affects Plaque Growth , 2004, Circulation.
[38] R. Ala-aho,et al. Matrix metalloproteinases as therapeutic targets in cancer. , 2005, Current cancer drug targets.
[39] K Ulrich Wendt,et al. Structural basis for the highly selective inhibition of MMP-13. , 2005, Chemistry & biology.
[40] Alexander D. MacKerell,et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.
[41] B. Baxter,et al. MMP-12 has a role in abdominal aortic aneurysms in mice , 2005 .
[42] S. Meroueh,et al. Quest for selectivity in inhibition of matrix metalloproteinases. , 2004, Current topics in medicinal chemistry.
[43] Constance E. Brinckerhoff,et al. Matrix metalloproteinases: a tail of a frog that became a prince , 2002, Nature Reviews Molecular Cell Biology.
[44] Yves Dumond,et al. Synthesis of Monosubstituted Phosphinic Acids: Palladium-Catalyzed Cross-Coupling Reactions of Anilinium Hypophosphite , 2001 .
[45] C. Whelan. Metalloprotease inhibitors as anti-inflammatory agents: an evolving target? , 2004, Current opinion in investigational drugs.
[46] C. Overall,et al. The Canonical Methionine 392 of Matrix Metalloproteinase 2 (Gelatinase A) Is Not Required for Catalytic Efficiency or Structural Integrity , 2004, Journal of Biological Chemistry.
[47] Peter Libby,et al. Atherosclerosis and proteinase activation. , 2006, Cardiovascular research.
[48] P Cuniasse,et al. Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs. , 2005, Biochimie.
[49] Günther Richter,et al. Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[50] E. Kerkelä,et al. Human macrophage metalloelastase (MMP-12) expression is induced in chondrocytes during fetal development and malignant transformation. , 2001, Bone.
[51] J. W. COOK,et al. A Text-Book of Practical Organic Chemistry , 1948, Nature.
[52] Z. Werb,et al. Regulation of matrix biology by matrix metalloproteinases. , 2004, Current opinion in cell biology.
[53] H. Stetter,et al. Eine einfache Herstellung von α-Alkylacrylsäure-estern , 1979 .
[54] P. Basset,et al. Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study. , 1999, Journal of medicinal chemistry.